Adverum Biotechnologies (NASDAQ:ADVM) Given New $33.00 Price Target at Chardan Capital
Adverum Biotechnologies (NASDAQ:ADVM – Free Report) had its price target reduced by Chardan Capital from $40.00 to $33.00 in a research note issued to investors on Thursday,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. A number of other research firms have also issued reports on ADVM. StockNews.com lowered shares […]
Adverum Biotechnologies (NASDAQ:ADVM – Free Report) had its price target reduced by Chardan Capital from $40.00 to $33.00 in a research note issued to investors on Thursday,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. A number of other research firms have also issued reports on ADVM. StockNews.com lowered shares […]
